Compounds > gemcitabine
Page last updated: 2024-08-24

gemcitabine and pf-477736

gemcitabine has been researched along with pf-477736 in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's5 (83.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Anderes, K; Arango, ME; Blasina, A; Chen, E; Chen, P; Grant, S; Hallin, J; Kraynov, E; Nichols, T; Ninkovic, S; O'Connor, P; Register, J1
Bingham, J; Blasina, A; Cao, J; Fang, DD; Gu, Y; Hostomsky, Z; Jani, JP; Jirout, Z; Kornmann, J; Lira, ME; Los, G; Tsaparikos, K; Vanarsdale, T; Wang, J; Zhu, Z1
Al-Ejeh, F; Biankin, AV; Brown, MP; Chou, A; Grimmond, SM; Kalimutho, M; Khanna, KK; Miranda, M; Nagrial, AM; Pajic, M; Shi, W1
Bryant, C; Massey, AJ; Rawlinson, R1
Kwiatkowski, DJ; Liu, Y1

Other Studies

6 other study(ies) available for gemcitabine and pf-477736

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:8

    Topics: Animals; Apoptosis; Benzodiazepinones; Cell Line; Checkpoint Kinase 1; Chromatography, Liquid; Deoxycytidine; DNA Damage; Dose-Response Relationship, Drug; Female; Gemcitabine; Histones; Humans; Male; Mice; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Rats; Rats, Sprague-Dawley; S Phase; Tandem Mass Spectrometry

2008
Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line.
    Frontiers of medicine, 2013, Volume: 7, Issue:4

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzodiazepinones; Biomarkers, Tumor; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Pyrazoles; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Spheroids, Cellular; Tumor Cells, Cultured

2013
Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Jun-15, Volume: 20, Issue:12

    Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Apoptosis; Benzodiazepinones; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Proliferation; Checkpoint Kinase 1; Combined Modality Therapy; Deoxycytidine; DNA Damage; Drug Synergism; ErbB Receptors; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Phosphorylation; Protein Kinases; Pyrazoles; Radioimmunotherapy; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2014
Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.
    BMC cancer, 2014, Aug-07, Volume: 14

    Topics: Benzodiazepinones; Biomarkers, Tumor; Cell Line, Tumor; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Indoles; MCF-7 Cells; Ovarian Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyridones; Thiophenes; Triple Negative Breast Neoplasms; Urea

2014
Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.
    Molecular cancer therapeutics, 2015, Volume: 14, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mice; Mutation; Protein Kinases; Pyrazoles; Thiophenes; Tumor Suppressor Protein p53; Urea; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays

2015